Article

A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important

Department of Surgical Oncology, Massachusetts General Hospital, 55 Fruit St., Yawkey Building, 7th Floor, Boston, MA 02114, USA.
The American Journal of Surgery (Impact Factor: 2.41). 11/2005; 190(4):517-20. DOI: 10.1016/j.amjsurg.2005.06.004
Source: PubMed

ABSTRACT Because neoadjuvant chemotherapy is being used more frequently, the optimal timing of sentinel node biopsy (SNB) remains controversial. We previously evaluated the predictive value of SNB before neoadjuvant chemotherapy in clinically node-negative breast cancer. Our identification rate of the sentinel node among 52 patients before chemotherapy with a mean tumor size of 4 cm was 100%. In this study, we compared the identification rates of SNB before and after neoadjuvant chemotherapy and evaluated the false-negative rate of SNB after chemotherapy.
A retrospective institutional database review identified 36 women who underwent SNB after neoadjuvant chemotherapy for breast cancer from 1999 to 2004. The initial clinical tumor size and lymph node status, SNB pathology, axillary lymph node dissection pathology, and residual pathologic tumor size were reviewed.
Sixteen of 36 patients had a clinically negative axilla before neoadjuvant therapy. SNB after neoadjuvant therapy was successful in 29 patients (80.6%), although 7 patients did not map (19.4%). Six of the 7 patients who failed to map had a clinically positive axilla initially. Axillary disease was found in 6 of 7 of these patients at dissection (85.7%). Of the 29 patients who mapped successfully, 13 (45%) were SNB negative, and 16 (55%) were SNB positive. Of the 13 SNB-negative patients, 2 had a positive axillary lymph node dissection, yielding a false-negative rate of 11%. Thirteen patients who mapped had a clinically positive axilla before therapy (45%). Of the 11 patients with true-negative SNBs, 7 (64%) were clinically node negative at presentation. The initial tumor sizes on examination ranged from 2 to 9 cm (mean, 5.0 cm), and residual pathologic tumor sizes ranged from 0 to 6 cm (mean, 1.8 cm). Failure to map correlated with a clinically positive axilla at presentation (100% vs 45%) but did not correlate with initial tumor size.
Sentinel node identification rates are significantly better when mapping is performed before neoadjuvant chemotherapy (100% vs 80.6%), with failure to map correlated with clinically positive nodal disease at presentation and residual disease at axillary lymph node dissection. Among patients who map successfully after chemotherapy, the false-negative rate is high (11%). Given these findings, we currently recommend SNB before neoadjuvant chemotherapy for clinically node-negative patients, and raise concerns about the use of SNB after neoadjuvant therapy in patients with an initially clinically positive axilla.

Full-text

Available from: Kevin S Hughes, Mar 05, 2015
0 Followers
 · 
101 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: PurposesAim of this study was to investigate the feasibility of sentinel lymph node biopsy(SLNB) after neoadjuant chemotherapy(NAC) in breast cancer patients with confirmed axillary nodal metastases.Methods We enrolled 51 patients with breast cancer who received NAC. All patients were proven to have axillary nodal metastases by Histopathology biopsy before NAC. They all underwent SLNB before breast surgery,and then complete axillary lymph node dissection followed immediately.ResultsThe identification rate for SLNB was 87.5 % (84/96); the false negative rate was 24.5%(12/49).The clinicopathological factors were not significantly correlated with the identification and the false negative rate of the SLNB. Method of lymphatic mapping, Blue dye or radionuclide method only have a trend to decrease the identification rate of SLNB (P=0.073). Clinical nodal status before NAC have a trend to increase the false-negative rates of the SLNB (P=0.059). For the patients with N1 clinical axillary lymph nodal status,the identification rate was 93.9%,and the false negative rate was 5.9%,compared with N2-3 patients 73.9% and 38.9%, respectively.ConlusionsSLNB is feasible for the patients whose axillary lymph nodal status before NAC was N1. However, for the N2-3 patients, SLN cannot be used as a infallible indicator of the non-SLN status.
    05/2014; 5(6). DOI:10.1111/1759-7714.12131
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The presence of nodal metastases is the most important prognostic indicator in breast cancer, making accurate assessment of the axillary nodal basin critical to delivering optimal therapy in breast cancer. Clinically node-negative women can be reliably staged in a minimally invasive manner using sentinel lymph node dissection (SLND). In node-negative patients receiving neoadjuvant chemotherapy, SLND can be performed after chemotherapy, allowing for a single surgical procedure and a decreased probability of requiring axillary lymph node dissection (ALND). Clinically node-positive patients are currently recommended to undergo ALND, although these recommendations may change with emerging trial data.
    Surgical Oncology Clinics of North America 07/2014; DOI:10.1016/j.soc.2014.03.007 · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The definition of locally advanced breast cancer (LABC) includes patients with large tumors, extensive regional lymph node involvement, or direct involvement of the skin or underlying chest wall. Neoadjuvant chemotherapy followed by surgery has become the standard of care and a valuable strategy in the multimodality management of LABC. Variations in practice exist and the purpose of this article is to explore the surgical considerations in the management of LABC. There exist various diagnostic and treatment considerations in LABC patients that help guiding clinicians in the optimal management of LABC. The evolving concepts of breast conservation, immediate breast reconstruction and optimal management of the axilla are addressed. LABC represents a heterogenous cohort of patients for whom a multidisciplinary care team is critical. A more detailed understanding of the surgical considerations will facilitate the optimal diagnostic evaluation and management of these patients.
    Current opinion in supportive and palliative care 01/2014; DOI:10.1097/SPC.0000000000000031